- Home
- IREN vs RPRX Comparison
IREN vs RPRX Comparison
Compare IREN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IREN | RPRX |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 22.0B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IREN | RPRX |
|---|---|---|
| Price | $38.84 | $57.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $62.50 | $51.40 |
| AVG Volume (30 Days) | ★ 36.5M | 3.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 234.48 | N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | $501,023,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $104.58 | $38.63 |
| Revenue Next Year | $200.20 | $4.73 |
| P/E Ratio | ★ N/A | $83.21 |
| Revenue Growth | ★ 167.65 | 5.06 |
| 52 Week Low | $14.72 | $34.63 |
| 52 Week High | $76.87 | $57.22 |
Technical Indicators
Market Signals| Indicator | IREN | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.72 | 62.25 |
| Support Level | $38.85 | $38.07 |
| Resistance Level | $46.88 | N/A |
| Average True Range (ATR) | 4.22 | 1.49 |
| MACD | -2.01 | 0.12 |
| Stochastic Oscillator | 4.72 | 95.31 |
Price Performance
Historical ComparisonAbout IREN Iris Energy Limited
IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operation. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.